Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity - A preliminary report

被引：64

作者：

Ducloux, D ^{[1
]}

Fournier, V

Bresson-Vautrin, C

Rebibou, JM

Billerey, C

Saint-Hillier, Y

Chalopin, JM

机构：

[1] Hop St Jacques, Dept Nephrol & Renal Transplantat, Besancon, France

[2] Hop St Jacques, Dept Anatomopathol, Besancon, France

来源：

TRANSPLANTATION | 1998年 / 65卷 / 11期

关键词：

D O I：

10.1097/00007890-199806150-00019

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background There is a great concern over cyclosporine (CsA) nephrotoxicity in renal transplant recipients, and the effects of conversion from CsA to azathioprine (AZA) remain controversial. Large studies have demonstrated that mycophenolate mofetil (MMF), the morpholinoethyl ester of mycophenolic acid, is superior to AZA as a posttransplant immunosuppressant. Methods. Six patients with isolated biopsy-proven CsA nephrotoxicity were converted from CsA-AZA to MMF. Results. Mean follow-up was 12+/-2 months. No patient experienced acute rejection. The mean serum creatinine concentration decreased from 225 +/- 58 to 159 +/- 66 mu mol/L (P < 0.0005), Hyperlipidemia and blood pressure improved after CsA withdrawal. Conclusion. In a selected transplant population with biopsy-proven CsA nephrotoxicity, CsA withdrawal with a concomitant switch from AZA to MMF seems to be safe and allows a significant improvement of renal function.

引用

页码：1504 / 1506

页数：3

共 10 条

[1] RENAL-TRANSPLANT FUNCTION AFTER 10 YEARS OF CYCLOSPORINE [J].

ALMOND, PS ;

GILLINGHAM, KJ ;

SIBLEY, R ;

MOSS, A ;

MELIN, M ;

LEVENTHAL, J ;

MANIVEL, C ;

KYRIAKIDES, P ;

PAYNE, WD ;

DUNN, DL ;

SUTHERLAND, DER ;

GORES, PF ;

NAJARIAN, JS ;

MATAS, AJ .

TRANSPLANTATION, 1992, 53 (02) :316-323

[2] RISK-FACTORS FOR CHRONIC REJECTION IN RENAL-ALLOGRAFT RECIPIENTS [J].

ALMOND, PS ;

MATAS, A ;

GILLINGHAM, K ;

DUNN, DL ;

PAYNE, WD ;

GORES, P ;

GRUESSNER, R ;

NAJARIAN, JS ;

FERGUSON ;

PAUL ;

SCHAFFER .

TRANSPLANTATION, 1993, 55 (04) :752-757

[3] RENAL-FUNCTION AND BLOOD-PRESSURE IN PATIENTS RECEIVING LONG-TERM, LOW-DOSE CYCLOSPORINE THERAPY FOR IDIOPATHIC AUTOIMMUNE UVEITIS [J].

DERAY, G ;

BENHMIDA, M ;

LEHOANG, P ;

MAKSUD, P ;

AUPETIT, B ;

BAUMELOU, A ;

JACOBS, C .

ANNALS OF INTERNAL MEDICINE, 1992, 117 (07) :578-583

[4]

EICH D, 1991, J HEART LUNG TRANSPL, V10, P45

[5] COMPARISON OF 3 IMMUNOSUPPRESSIVE REGIMENS IN CADAVER RENAL-TRANSPLANTATION - LONG-TERM CYCLOSPORINE, SHORT-TERM CYCLOSPORINE FOLLOWED BY AZATHIOPRINE AND PREDNISOLONE, AND AZATHIOPRINE AND PREDNISOLONE WITHOUT CYCLOSPORINE [J].

HALL, BM ;

TILLER, DJ ;

HARDIE, I ;

MAHONY, J ;

MATHEW, T ;

THATCHER, G ;

MIACH, P ;

THOMSON, N ;

SHEIL, AGR .

NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (23) :1499-1507

[6] Mycophenolate mofetil in renal allograft recipients - A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection [J].

Halloran, P ;

Mathew, T ;

Tomlanovich, S ;

Groth, C ;

Hooftman, L ;

Barker, C .

TRANSPLANTATION, 1997, 63 (01) :39-47

[7]

MEYERS BD, 1984, NEW ENGL J MED, V311, P699

[8] A CONTROLLED TRIAL OF CYCLOSPORINE IN RENAL-TRANSPLANTATION WITH CONVERSION TO AZATHIOPRINE AND PREDNISOLONE AFTER 3 MONTHS [J].

MORRIS, PJ ;

FRENCH, ME ;

DUNNILL, MS ;

HUNNISETT, AGW ;

TING, A ;

THOMPSON, JF ;

WOOD, RFM .

TRANSPLANTATION, 1983, 36 (03) :273-277

[9] CHRONIC INJURY OF HUMAN RENAL MICROVESSELS WITH LOW-DOSE CYCLOSPORINE THERAPY [J].

MYERS, BD ;

NEWTON, L ;

BOSHKOS, C ;

MACOVIAK, JA ;

FRIST, WH ;

DERBY, GC ;

PERLROTH, MG ;

SIBLEY, RK .

TRANSPLANTATION, 1988, 46 (05) :694-703

[10] AN INCREASED INCIDENCE OF LATE ACUTE REJECTION EPISODES IN CADAVER RENAL-ALLOGRAFT RECIPIENTS GIVEN AZATHIOPRINE, CYCLOSPORINE, AND PREDNISONE [J].

WRENSHALL, LE ;

MATAS, AJ ;

CANAFAX, DM ;

MIN, DI ;

SIBLEY, RJ ;

DUNN, DL ;

PAYNE, WD ;

SUTHERLAND, DER ;

NAJARIAN, JS .

TRANSPLANTATION, 1990, 50 (02) :233-237

← 1 →